Navigation Links
Replidyne and Cardiovascular Systems Sign Merger Agreement
Date:11/4/2008

nced a limited commercial introduction of the product in the U.S. in September 2007 and began full commercial launch in the first calendar quarter of 2008. Through September 30, 2008, nearly 11,000 Diamondback devices have been sold to more than 280 hospitals.

Management and Organization

The combined company will be headed by CSI's Martin and CSI's executive team. The combined board of directors will consist of 10 members, including two current Replidyne directors, Edward Brown and Augustine Lawlor. The Chairman of the Board will be Glen D. Nelson, M.D., currently Chairman of CSI. The other members of the combined Board of Directors will be Brent Blackey, John Friedman, Geoffrey Hartzler, M.D., Roger Howe, Ph.D., Michael Kallok, Ph.D., David Martin and Gary Petrucci.

Conference Call Today at 8:30AM ET

Replidyne and CSI will host a joint conference call Tuesday, November 4, 2008 at 8:30 AM ET (7:30 AM CT, 5:30 AM PT) to discuss this transaction. Callers may participate in the conference call by dialing 800-329-9097 (domestic) or 617-614-4929 (international), and providing the passcode 89012165. To access the live webcast, log on Replidyne's website at http://www.Replidyne.com and go to the Investor Relations section.

A replay of the conference call will be available approximately one hour after the completion of the call through Tuesday, November 11, 2008 at midnight. Callers may access the replay by dialing 888-286-8010 (U.S. participants) or 617-801-6888 (international participants). The audio replay passcode is 13353327. To access a replay of the webcast, visit the Investor Relations section of Replidyne's website at http://www.Replidyne.com.

Additional information about this transaction is available online at http://www.Replidyne.com or

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Replidyne Announces Second Quarter 2008 Results From Operations
2. Replidyne Terminates Faropenem Agreements
3. Replidyne to Report First Quarter 2008 Earnings
4. Replidyne Announces 2007 Fourth Quarter and Full Year Results
5. Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
6. Replidyne to Announce Third Quarter 2007 Earnings
7. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
8. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
9. CorMatrix Cardiovascular to Present Data on Its Next Generation ECM Technology(TM) at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, D.C.
10. Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm
11. Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During Live Case at the Paris Cardiovascular Interventions Course (Francophone) 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Inc. (OTC: MSEL) operating under its principal brand ... of visual communications and brand imaging solutions, was awarded " ... 9th Annual American Business Awards Ceremony, in recognition of its ... solid results, despite prevailing economic turbulence. The American ...
... 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: ... present data for its two first-in-class diabetes drugs, ... and its investigational diabetes drug candidates BYDUREON™ (exenatide ... at the 71st Scientific Sessions of the American ...
... 2011 Scientists Drs. Samuel and Elenore Bogoch of BioRadar ... in Replikin Counts of the EHEC lethal strains of E. ... of E. Coli have been studied in laboratories in Germany ... in the public databases. Replikins are subsequences of the genome ...
Cached Biology Technology:Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 2Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 3Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 4Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 5Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 2Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 3Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 4Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 5Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 6Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 7Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 8Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... news release is available in German . ... millions of sperms every day in order to reproduce? And ... are the topic of the latest issue of the research ... 2014). The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld ... it is not unusual for a female to copulate with ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... top technological universities have come together to form ... brings together these leading engineering-based universities in the ... address global societal issues is through the joint ... top class research in science and technology. ...
... Scientists have completed the first study of microbes that ... the Gulf of Mexico, where conditions may resemble those ... was partially funded by the National Science Foundation (NSF), ... vents spew mud, oil, brine and gases that support ...
... Outreach efforts by the Translational Genomics Research Institute (TGen) ... the second year, TGen will help organize a cancer ... The 2nd annual Fort Defiance Cancer Awareness and Advocacy ... 8:30 a.m.-5 p.m. July 18 at the Navajo Nation ...
Cached Biology News:Global alliance of leading technological universities to address global societal issues 2Better living through chemistry 2Better living through chemistry 3TGen helps promote cancer awareness for vast Navajo Nation 2TGen helps promote cancer awareness for vast Navajo Nation 3
...
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Acetyl CoA Carboxylase Antibody...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Biology Products: